Clinical trial Recruiting at 2 sites Observational Ages 50 to 70

Heart failure with preserved ejection fraction in people with COPD: clinical course and prognosis

Official title: Heart Failure With Preserved Ejection Fraction in Patients With Сhronic Obstructive Pulmonary Disease: Clinical Course and Prognosis

Run by National Medical Research Center for Therapy and Preventive Medicine · NCT07375433 · Data updated 2026-11-12

This project will see how often HFpEF appears in people aged 50–70 hospitalized with COPD and whether having HFpEF changes their symptoms, exercise capacity, and prognosis.

Quick facts

Study typeObservational
Ages50 Years to 70 Years
SexAll
Enrollment200 (estimated)
SponsorNational Medical Research Center for Therapy and Preventive Medicine
Government
Locations2 sites (Kazan' and 1 other locations)
StatusRecruiting
StartedJanuary 1, 2026
Main results expectedDecember 31, 2026
Study endsDecember 31, 2026
Registry record updatedFebruary 10, 2026
Trial IDNCT07375433 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are Russian citizens aged 50–70 with a verified diagnosis of COPD who are hospitalized at a participating center and can give informed consent.

Probably not a fit

People without COPD, those outside the 50–70 age range, individuals with other decompensated chronic diseases, or those unable to consent (including non‑Russian citizens) are unlikely to benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study compares HFpEF detection rates in hospitalized COPD patients and examines how the presence of HFpEF affects clinical course and outcomes. Investigators will perform a retrospective chart review to identify previously undiagnosed HFpEF and compare recorded diagnoses with echocardiographic and hemodynamic criteria. Routine blood tests and biomarker analysis, echocardiography (including epicardial adipose tissue thickness and E/e'), spirometry, body plethysmography, and a 6‑minute walk test will be used to characterize participants. The study is conducted at sites in Kazan and Moscow and enrolls Russian citizens aged 50–70 hospitalized for COPD.

Why it matters

Potential benefit: If successful, earlier recognition of HFpEF in people with COPD could allow more targeted treatment and potentially improve symptoms and long‑term outcomes.

How similar studies have gone: Previous observational studies have documented overlap between COPD and HFpEF and shown that HFpEF is associated with worse functional status and prognosis, so this work builds on established findings rather than testing an entirely novel concept.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Verified diagnosis of COPD;
2. Patients hospitalized with COPD;
3. Citizenship of the Russian Federation;
4. Patients aged 50 to 70 years;
5. Patient consent to participate in the study.

Exclusion Criteria:

1. Lack of Russian Federaion citizenship;
2. Patient's refusal to participate in the study;
3. Any chronic diseases, other than COPD, that affect the prognosis, in the acute and/or decompensated stage;
4. Mental disorders.

Where it's running

  • Kazan State Medical University
    Kazan', Russia
    Recruiting
  • National Medical Research Center for Therapy and Preventive Medicine
    Moscow, Russia
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.